Literature DB >> 7825688

Excimer laser filtration surgery.

A M Brooks1, M Samuel, N Carroll, N Downie, H R Taylor.   

Abstract

PURPOSE: In order to remove precisely scleral tissue overlying Schlemm's canal with minimal trauma as an outpatient procedure under local anesthetic, we used a VisX Twenty/Twenty excimer laser.
METHODS: We performed excimer laser filtration in three enucleated pig eyes, seven enucleated human eyes, and seven eyes of seven patients with severe glaucoma. Precise ablation to Schlemm's canal was confirmed by scanning electron microscopy in the enucleated eyes. For the patients, a local anesthetic was used, and a custom-made holder was used to mobilize the conjunctiva and fix the eye.
RESULTS: A functional sclerostomy was obtained with 1,780 to 5,965 pulses, using a 2 x 1-mm slit. In our mean follow-up of nine months (range, six to 12 months) the excimer laser filtration technique achieved controlled filtration in five of seven patients and minimized conjunctival trauma. One patient subsequently underwent cataract extraction.
CONCLUSIONS: This study indicates that excimer laser filtration is an effective technique for achieving filtration in glaucoma. It may reduce the complications of glaucoma filtration surgery, particularly the incidence of shallow anterior chamber postoperatively, as it leaves the trabecular meshwork intact.

Entities:  

Mesh:

Year:  1995        PMID: 7825688     DOI: 10.1016/s0002-9394(14)73811-5

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  2 in total

1.  In vivo femtosecond laser subsurface scleral treatment in rabbit eyes.

Authors:  Dongyul Chai; Gautam Chaudhary; Eric Mikula; Hui Sun; Ron Kurtz; Tibor Juhasz
Journal:  Lasers Surg Med       Date:  2010-09       Impact factor: 4.025

2.  Experimental studies on nonpenetrating filtration surgery using the CO2 laser.

Authors:  Ehud I Assia; Yigal Rotenstreich; Irina S Barequet; David J Apple; Mordechai Rosner; Michael Belkin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-13       Impact factor: 3.535

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.